Hypertension is the single most important risk factor or worldwide mortality and morbidity in both developed and developing countries. Evidence from a large number of prospective randomized controlled clinical trials supports the importance of optimal reduction of BP as a strategy to reduce global cardiovascular risk. Current national guidelines emphasize the importance of appropriate selection of specific drug classes to optimize reduction of the burden of target organ disease depending on the presence of major morbid conditions such as heart failure, previous myocardial infarction, high CAD risk, diabetes, chronic kidney disease or stroke.
In the absence of such compelling indications for specific anti-hypertensive drug classes, diuretics are generally recommended as first line anti-hypertensive therapy or as additional therapy in patients on other anti-hypertensive drug classes who are not yet at goal. This recommendation is based on the conclusion that no other class of anti-hypertensive drugs has been shown in any randomized clinical outcome trials to be superior to diuretics in reducing cardiovascular risk.
The intended result of this activity is increased knowledge. At the conclusion of this program, participants will be able to
Recognize the importance of optimal reduction of BP in reducing cardiovascular disease risk.
Select appropriate pharmacological and life style modification strategies to reduce cardiovascular risk in high risk hypertensive patients.
Follow JNC 7 guidelines for managing hypertensive patients.
Individuals who will benefit by participating in this CME enduring material include cardiologists, cardiovascular surgeons, physicians and others interested in clinical trials related to diagnosis and treatment of hypertention.
Measuring Adherence to Practice Guidelines for the Management of Hypertension
Guidelines for Hypertension: Are Quality-Assurance Measures on Target?
Evaluation / Feedback
We value your comments; please send your suggestions and comments to the office of continuing medical education at the Texas Heart Institute.
Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Texas Heart Institute designates this educational activity for a maximum of 1 Category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.
The estimated time to complete this activity, including review of the materials is 1 hours.
Term of Approval
January 2006 through January 2009. Original release date: January 30, 2006.
In January 2005, this continuing medical education activity was reviewed by James J. Ferguson III, MD, FACC Associate Director, Clinical Cardiology Research, THI; Co-Chairman, Medical Education Committee, THI; Chairman, Research Committee, THI. Houston, TX.
Disclosure of Relationships
It is the intent of the Texas Heart Institute to assure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program.
In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, faculty members have disclosed all relationships with any of the manufacturers of commercial products discussed or with either one or more of the corporate organizations offering educational grants for this continuing medical education activity.
Dr. Habib does not have any financial interest or other relationship with any of the manufacturer(s) of any commercial product(s) discussed in his presentation.
Return to event home page.